Hafnia alvei HA4597® is a novel probiotic strain producing an anorexigenic mimetic protein. This report summarizes the innovative approach leading to the discovery of the precision probiotic H. alvei HA4597® and its benefits on body weight and metabolic parameters. H. alvei HA4597® has been identified after the striking findings on the effects of the bacterial metabolite ClpB (Caseinolytic peptidase B) on appetite regulation, through a screening of ClpB-producing strains. Its efficacy in humans has been validated by a multicentric, double-blind, randomized placebo-controlled trial including 236 overweight adults. The successful results on body weight loss of the clinical study support the use of H. alvei HA4597® in the global management of excess weight.
Part of the book: Weight Management